The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...
1don MSN
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...
Eli Lilly announces plans to build four new U.S. manufacturing facilities, enhancing domestic pharmaceutical production and creating jobs.
The new plants will be built over the next five years, and are expected to create more than 3,000 jobs for skilled workers.
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
US pharmaceutical giant Eli Lilly announced Wednesday that it will build four additional new manufacturing sites in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results